(Source: NuPathe Inc) · Accretive transaction furthers Endo's transformation into leading specialty healthcare company · Builds on Endo's leadership in pain management through addition of ZECUITY® (sumatriptan iontophoretic transdermal system), the first and only FDA approved patch to treat migraine · Proven Endo branded pharmaceuticals commercial team to execute ZECUITY launch, expected in first half 2014 MALVERN, Pa. - Dec. 16, 2013 - Endo Health Solutions (Nasdaq: ENDP) today announced it has entered into a definitive agreement under which Endo will acquire NuPathe Inc. (Nasdaq: PATH) for $2.85 per share in cash, or approximately $105 million. In addition to the upfront cash...
↧